trending Market Intelligence /marketintelligence/en/news-insights/trending/w4yWVTZNK-DrTaI_0VAx-A2 content esgSubNav
In This List

Aclaris Therapeutics to cut 86 jobs in restructuring

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aclaris Therapeutics to cut 86 jobs in restructuring

Aclaris Therapeutics Inc. is cutting 86 staff as part of a restructuring to refocus resources on the development of its drug pipeline.

The Wayne, Pa.-based biopharmaceutical company, which develops and commercializes treatments for skin disorders and immuno-inflammatory diseases, said it is also seeking partners for its commercial products business.

Aclaris said it will not use a sales force to promote Rhofade and is looking for strategic partners for Eskata and its experimental topical solution for common warts, A-101.

Additionally, the company is seeking a development and commercialization partner for ATI-501 and ATI-502, drug candidates for treating a hair loss condition.

Aclaris will pursue the development of another treatment, ATI-450, for rheumatoid arthritis, and will keep investing in ATI-1777 and other preclinical drug candidates for immuno-inflammatory diseases.

The total restructuring cost will be in the range of $3 million to $3.5 million, Aclaris noted in its Sept. 5 press release.